DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer
DBV Technologies (NASDAQ: DBVT), a clinical-stage biopharmaceutical company, has appointed James Briggs as its new Chief Human Resources Officer, replacing Caroline Daniere. This strategic appointment comes as DBV prepares for its transition from a development-stage biotech to a potential commercial organization.
Briggs, who will report to CEO Daniel Tassé and join the Executive Committee, brings significant experience as a former Partner at East Bay Human Capital and CEO of MNG Health. He previously served as CHRO at several organizations including Ciox Health and Ikaria Inc. Briggs holds a Master's in Human Relations, is SPHR certified, and has a Six Sigma Green Belt certification.
DBV Technologies (NASDAQ: DBVT), un'azienda biofarmaceutica in fase clinica, ha nominato James Briggs come nuovo Chief Human Resources Officer, in sostituzione di Caroline Daniere. Questa nomina strategica avviene mentre DBV si prepara a passare da una biotech in fase di sviluppo a una potenziale organizzazione commerciale.
Briggs, che riporterà direttamente al CEO Daniel Tassé e entrerà a far parte del Comitato Esecutivo, porta con sé una vasta esperienza come ex Partner di East Bay Human Capital e CEO di MNG Health. In precedenza ha ricoperto il ruolo di CHRO in diverse aziende, tra cui Ciox Health e Ikaria Inc. Briggs è in possesso di un Master in Relazioni Umane, certificazione SPHR e certificazione Six Sigma Green Belt.
DBV Technologies (NASDAQ: DBVT), una compañía biofarmacéutica en etapa clínica, ha nombrado a James Briggs como su nuevo Chief Human Resources Officer, reemplazando a Caroline Daniere. Este nombramiento estratégico ocurre mientras DBV se prepara para su transición de una biotecnológica en etapa de desarrollo a una posible organización comercial.
Briggs, quien reportará al CEO Daniel Tassé y se unirá al Comité Ejecutivo, aporta una amplia experiencia como ex socio de East Bay Human Capital y CEO de MNG Health. Anteriormente se desempeñó como CHRO en varias organizaciones, incluyendo Ciox Health e Ikaria Inc. Briggs tiene una maestría en Relaciones Humanas, está certificado como SPHR y posee la certificación Six Sigma Green Belt.
DBV Technologies (NASDAQ: DBVT)는 임상 단계의 생명공학 회사로, James Briggs를 새로운 최고인사책임자(CHRO)로 임명했으며, Caroline Daniere를 대신합니다. 이 전략적 임명은 DBV가 개발 단계의 바이오텍에서 잠재적인 상업 조직으로 전환을 준비하는 시점에 이루어졌습니다.
Briggs는 CEO Daniel Tassé에게 보고하며 경영진 위원회에 합류할 예정입니다. 그는 East Bay Human Capital의 전 파트너이자 MNG Health의 CEO로서 풍부한 경험을 보유하고 있습니다. 또한 Ciox Health와 Ikaria Inc. 등 여러 기관에서 CHRO로 근무한 경력이 있습니다. Briggs는 인간관계 석사 학위를 보유하고 있으며, SPHR 자격증과 Six Sigma Green Belt 인증을 받았습니다.
DBV Technologies (NASDAQ : DBVT), une entreprise biopharmaceutique en phase clinique, a nommé James Briggs en tant que nouveau Chief Human Resources Officer, remplaçant Caroline Daniere. Cette nomination stratégique intervient alors que DBV se prépare à passer d'une biotech en phase de développement à une organisation potentiellement commerciale.
Briggs, qui rapportera directement au PDG Daniel Tassé et rejoindra le Comité Exécutif, apporte une solide expérience en tant qu'ancien associé chez East Bay Human Capital et PDG de MNG Health. Il a précédemment occupé le poste de CHRO dans plusieurs organisations, notamment Ciox Health et Ikaria Inc. Briggs est titulaire d'un Master en Relations Humaines, certifié SPHR et détient une certification Six Sigma Green Belt.
DBV Technologies (NASDAQ: DBVT), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat James Briggs als neuen Chief Human Resources Officer ernannt und ersetzt damit Caroline Daniere. Diese strategische Ernennung erfolgt, während sich DBV auf den Übergang von einem Entwicklungs-Biotech zu einer potenziellen kommerziellen Organisation vorbereitet.
Briggs, der direkt an CEO Daniel Tassé berichten und dem Executive Committee beitreten wird, bringt umfangreiche Erfahrung mit, unter anderem als ehemaliger Partner bei East Bay Human Capital und CEO von MNG Health. Zuvor war er CHRO bei mehreren Organisationen, darunter Ciox Health und Ikaria Inc. Briggs besitzt einen Masterabschluss in Human Relations, ist SPHR-zertifiziert und hat eine Six Sigma Green Belt Zertifizierung.
- None.
- None.
Châtillon, France, July 22, 2025
DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of James Briggs as its Chief Human Resources Officer, succeeding Caroline Daniere. An experienced human capital executive, James will lead key initiatives as DBV transitions from a development-stage biotechnology company to a potential commercial organization. Mr. Briggs will report directly to Daniel Tassé, Chief Executive Officer, and serve as a member of the Executive Committee.
“I want to thank Caroline for her extraordinary leadership and express sincere gratitude for the teams she has built and the culture she has cultivated,” said Daniel Tassé Chief Executive Officer, DBV Technologies. "Like Caroline, James has a rare eye for talent and ability to find the right people-driven solutions. His proven track record in driving enterprise value through talent strategy and organizational transformation will be invaluable as we scale our operations and prepare for potential commercialization."
Most recently, Mr. Briggs served as Partner at East Bay Human Capital, a human resources consulting firm specializing in human capital strategy, change management, and organizational design. Previously, he held several executive roles, including Chief Executive Officer at MNG Health, where he led the successful turnaround and sale of the healthcare technology company. He also served as Chief Human Resources Officer at multiple organizations, including Ciox Health and Ikaria Inc.
"This is a pivotal moment for DBV as we prepare to transition from our clinical development focus to building the infrastructure and capabilities needed for commercial success," said James Briggs. "I'm excited to join this talented leadership team and help build upon the organizational foundation that will support our mission to bring life-changing treatments to patients who need them most."
Mr. Briggs holds a Master's degree in Human Relations and a Bachelor's degree in Communications from the University of Illinois at Urbana-Champaign. He is a certified Senior Professional in Human Resources (SPHR) and a Six Sigma Green Belt.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
FAQ
Who is the new Chief Human Resources Officer at DBV Technologies (DBVT)?
What is James Briggs' background before joining DBV Technologies?
Why did DBV Technologies (DBVT) appoint a new CHRO in July 2025?
What are James Briggs' qualifications at DBV Technologies?
Who will James Briggs report to at DBV Technologies (DBVT)?
